Mesenchymal stem cell subpopulations: phenotype, property and therapeutic potential

Friedenstein AJ, Chailakhjan RK, Lalykina KS (1970) The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 3(4):393–403 Dmitrieva RI, Minullina IR, Bilibina AA et al (2012) Bone marrow- and subcutaneous adipose tissue-derived mesenchymal stem cells: differences and similarities. Cell Cycle 11(2):377–383. doi:10.4161/cc.11.2.18858 Soncini M, Vertua E, Gibelli L et al (2007) Isolation and characterization of mesenchymal cells from human fetal membranes. J Tissue Eng Regen Med 1(4):296–305. doi:10.1002/term.40 Yang ZX, Han ZB, Ji YR et al (2013) CD106 identifies a subpopulation of mesenchymal stem cells with unique immunomodulatory properties. PLoS One 8(3):e59354. doi:10.1371/journal.pone.0059354 Xu J, Liao W, Gu D et al (2009) Neural ganglioside GD2 identifies a subpopulation of mesenchymal stem cells in umbilical cord. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 23(4–6):415–424. doi:10.1159/000218188 Pittenger MF, Mackay AM, Beck SC et al (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284(5411):143–147 Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views. Stem Cells 25(11):2896–2902. doi:10.1634/stemcells.2007-0637 Liechty KW, MacKenzie TC, Shaaban AF et al (2000) Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 6(11):1282–1286. doi:10.1038/81395 Lin RZ, Moreno-Luna R, Li D et al (2014) Human endothelial colony-forming cells serve as trophic mediators for mesenchymal stem cell engraftment via paracrine signaling. Proc Natl Acad Sci USA 111(28):10137–10142. doi:10.1073/pnas.1405388111 Wu Y, Chen L, Scott PG et al (2007) Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25(10):2648–2659. doi:10.1634/stemcells.2007-0226 Wu Y, Zhao RC, Tredget EE (2010) Concise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. Stem Cells 28(5):905–915. doi:10.1002/stem.420 Chamberlain J, Yamagami T, Colletti E et al (2007) Efficient generation of human hepatocytes by the intrahepatic delivery of clonal human mesenchymal stem cells in fetal sheep. Hepatology 46(6):1935–1945. doi:10.1002/hep.21899 Tamai K, Yamazaki T, Chino T et al (2011) PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci USA 108(16):6609–6614. doi:10.1073/pnas.1016753108 Parekkadan B, Milwid JM (2010) Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 12:87–117. doi:10.1146/annurev-bioeng-070909-105309 Kim YS, Park EH, Kim YC et al (2013) Clinical outcomes of mesenchymal stem cell injection with arthroscopic treatment in older patients with osteochondral lesions of the talus. Am J Sports Med 41(5):1090–1099. doi:10.1177/0363546513479018 Trounson A, McDonald C (2015) Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 17(1):11–22. doi:10.1016/j.stem.2015.06.007 Lv FJ, Tuan RS, Cheung KM et al (2014) Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells 32(6):1408–1419. doi:10.1002/stem.1681 Rostovskaya M, Anastassiadis K (2012) Differential expression of surface markers in mouse bone marrow mesenchymal stromal cell subpopulations with distinct lineage commitment. PLoS One 7(12):e51221. doi:10.1371/journal.pone.0051221 Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315–317. doi:10.1080/14653240600855905 Phinney DG (2012) Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem 113(9):2806–2812. doi:10.1002/jcb.24166 Tormin A, Brune JC, Olsson E et al (2009) Characterization of bone marrow-derived mesenchymal stromal cells (MSC) based on gene expression profiling of functionally defined MSC subsets. Cytotherapy 11(2):114–128. doi:10.1080/14653240802716590 Arufe MC, De la Fuente A, Fuentes I et al (2010) Chondrogenic potential of subpopulations of cells expressing mesenchymal stem cell markers derived from human synovial membranes. J Cell Biochem 111(4):834–845. doi:10.1002/jcb.22768 Colter DC, Sekiya I, Prockop DJ (2001) Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci USA 98(14):7841–7845. doi:10.1073/pnas.141221698 Prockop DJ, Sekiya I, Colter DC (2001) Isolation and characterization of rapidly self-renewing stem cells from cultures of human marrow stromal cells. Cytotherapy 3(5):393–396. doi:10.1080/146532401753277229 Lee RH, Hsu SC, Munoz J et al (2006) A subset of human rapidly self-renewing marrow stromal cells preferentially engraft in mice. Blood 107(5):2153–2161. doi:10.1182/blood-2005-07-2701 Iinuma S, Aikawa E, Tamai K et al (2015) Transplanted bone marrow-derived circulating PDGFRalpha+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft. J Immunol 194(4):1996–2003. doi:10.4049/jimmunol.1400914 Mabuchi Y, Morikawa S, Harada S et al (2013) LNGFR(+)THY-1(+)VCAM-1(hi +) cells reveal functionally distinct subpopulations in mesenchymal stem cells. Stem cell reports 1(2):152–165. doi:10.1016/j.stemcr.2013.06.001 Seeger FH, Rasper T, Koyanagi M et al (2009) CXCR4 expression determines functional activity of bone marrow-derived mononuclear cells for therapeutic neovascularization in acute ischemia. Arterioscler Thromb Vasc Biol 29(11):1802–1809. doi:10.1161/ATVBAHA.109.194688 Lane SW, Williams DA, Watt FM (2014) Modulating the stem cell niche for tissue regeneration. Nat Biotech 32(8):795–803. doi:10.1038/nbt.2978 Jiang Y, Jahagirdar BN, Reinhardt RL et al (2002) Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418(6893):41–49. doi:10.1038/nature00870 Kuroda Y, Kitada M, Wakao S et al (2010) Unique multipotent cells in adult human mesenchymal cell populations. Proc Natl Acad Sci USA 107(19):8639–8643. doi:10.1073/pnas.0911647107 Han B, Li J, Li Z et al (2013) Trichostatin A stabilizes the expression of pluripotent genes in human mesenchymal stem cells during ex vivo expansion. PLoS One 8(11):e81781. doi:10.1371/journal.pone.0081781 Li Z, Liu C, Xie Z et al (2011) Epigenetic dysregulation in mesenchymal stem cell aging and spontaneous differentiation. PLoS One 6(6):e20526. doi:10.1371/journal.pone.0020526 Ning H, Lin G, Lue TF et al (2011) Mesenchymal stem cell marker Stro-1 is a 75 kd endothelial antigen. Biochem Biophys Res Comm 413(2):353–357. doi:10.1016/j.bbrc.2011.08.104 Lin G, Liu G, Banie L et al (2011) Tissue distribution of mesenchymal stem cell marker Stro-1. Stem Cells Dev 20(10):1747–1752. doi:10.1089/scd.2010.0564 Psaltis PJ, Paton S, See F et al (2010) Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. J Cell Physiol 223(2):530–540. doi:10.1002/jcp.22081 Bensidhoum M, Chapel A, Francois S et al (2004) Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood 103(9):3313–3319. doi:10.1182/blood-2003-04-1121 Samsonraj RM, Rai B, Sathiyanathan P et al (2015) Establishing criteria for human mesenchymal stem cell potency. Stem Cells 33(6):1878–1891. doi:10.1002/stem.1982 Zannettino AC, Paton S, Kortesidis A et al (2007) Human mulipotential mesenchymal/stromal stem cells are derived from a discrete subpopulation of STRO-1bright/CD34/CD45(-)/glycophorin-A-bone marrow cells. Haematologica 92(12):1707–1708. doi:10.3324/haematol.11691 Simmons PJ, Torokstorb B (1991) Identification of stromal cell precursors in human bone-marrow by a novel monoclonal-antibody, Stro-1. Blood 78(1):55–62 Martens TP, See F, Schuster MD et al (2006) Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. Nature Clin Pract Cardiovasc Med 3(Suppl 1):S18–S22. doi:10.1038/ncpcardio0404 Thomson TM, Rettig WJ, Chesa PG et al (1988) Expression of human nerve growth factor receptor on cells derived from all three germ layers. Exp Cell Res 174(2):533–539 Busser H, Najar M, Raicevic G et al (2015) Isolation and characterization of human mesenchymal stromal cell subpopulations: comparison of bone marrow and adipose tissue. Stem Cells Dev 24(18):2142–2157. doi:10.1089/scd.2015.0172 Quirici N, Soligo D, Bossolasco P et al (2002) Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 30(7):783–791 Iso Y, Yamaya S, Sato T et al (2012) Distinct mobilization of circulating CD271+ mesenchymal progenitors from hematopoietic progenitors during aging and after myocardial infarction. Stem Cells Transl Med 1(6):462–468. doi:10.5966/sctm.2011-0051 Cuthbert R, Boxall SA, Tan HB et al (2012) Single-platform quality control assay to quantify multipotential stromal cells in bone marrow aspirates prior to bulk manufacture or direct therapeutic use. Cytotherapy 14(4):431–440. doi:10.3109/14653249.2011.651533 Cuthbert RJ, Giannoudis PV, Wang XN et al (2015) Examining the feasibility of clinical grade CD271+ enrichment of mesenchymal stromal cells for bone regeneration. PLoS One 10(3):e0117855. doi:10.1371/journal.pone.0117855 Churchman SM, Ponchel F, Boxall SA et al (2012) Transcriptional profile of native CD271+ multipotential stromal cells: evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling activity. Arthritis Rheum 64(8):2632–2643. doi:10.1002/art.34434 Mifune Y, Matsumoto T, Murasawa S et al (2013) Therapeutic superiority for cartilage repair by CD271-positive marrow stromal cell transplantation. Cell Transplant 22(7):1201–1211. doi:10.3727/096368912X657378 Kuci S, Kuci Z, Kreyenberg H et al (2010) CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica 95(4):651–659. doi:10.3324/haematol.2009.015065 Li H, Ghazanfari R, Zacharaki D et al (2014) Low/negative expression of PDGFR-alpha identifies the candidate primary mesenchymal stromal cells in adult human bone marrow. Stem Cell Report 3(6):965–974. doi:10.1016/j.stemcr.2014.09.018 Battula VL, Treml S, Bareiss PM et al (2009) Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica 94(2):173–184. doi:10.3324/haematol.13740 Noort WA, Oerlemans MI, Rozemuller H et al (2012) Human versus porcine mesenchymal stromal cells: phenotype, differentiation potential, immunomodulation and cardiac improvement after transplantation. J Cell Mol Med 16(8):1827–1839. doi:10.1111/j.1582-4934.2011.01455.x Latifi-Pupovci H, Kuci Z, Wehner S et al (2015) In vitro migration and proliferation (“wound healing”) potential of mesenchymal stromal cells generated from human CD271(+) bone marrow mononuclear cells. J Transl Med 13:315. doi:10.1186/s12967-015-0676-9 Duff SE, Li C, Garland JM et al (2003) CD105 is important for angiogenesis: evidence and potential applications. FASEB J Off Publ Fed Am Soc Exp Biol 17(9):984–992. doi:10.1096/fj.02-0634rev Gaebel R, Furlani D, Sorg H et al (2011) Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration. PLoS One 6(2):e15652. doi:10.1371/journal.pone.0015652 Pierelli L, Bonanno G, Rutella S et al (2001) CD105 (endoglin) expression on hematopoietic stem/progenitor cells. Leuk Lymph 42(6):1195–1206. doi:10.3109/10428190109097744 Noiseux N, Gnecchi M, Lopez-Ilasaca M et al (2006) Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther J Am Soc Gene Ther 14(6):840–850. doi:10.1016/j.ymthe.2006.05.016 Silva GV, Litovsky S, Assad JA et al (2005) Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 111(2):150–156. doi:10.1161/01.CIR.0000151812.86142.45 Conconi MT, Burra P, Di Liddo R et al (2006) CD105(+) cells from Wharton’s jelly show in vitro and in vivo myogenic differentiative potential. Int J Mol Med 18(6):1089–1096 Roura S, Farre J, Soler-Botija C et al (2006) Effect of aging on the pluripotential capacity of human CD105 +mesenchymal stem cells. Eur J Heart Fail 8(6):555–563. doi:10.1016/j.ejheart.2005.11.006 Ranganath SH, Levy O, Inamdar MS et al (2012) Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10(3):244–258. doi:10.1016/j.stem.2012.02.005 Li N, Wang C, Jia L et al (2014) Heart regeneration, stem cells, and cytokines. Regen Med Res 2(1):6. doi:10.1186/2050-490X-2-6 Iohara K, Imabayashi K, Ishizaka R et al (2011) Complete pulp regeneration after pulpectomy by transplantation of CD105 + stem cells with stromal cell-derived factor-1. Tissue Eng Part A 17(15–16):1911–1920. doi:10.1089/ten.TEA.2010.0615 Pettine KA, Murphy MB, Suzuki RK et al (2015) Percutaneous injection of autologous bone marrow concentrate cells significantly reduces lumbar discogenic pain through 12 months. Stem Cell 33(1):146–156. doi:10.1002/stem.1845 Alon R, Kassner PD, Carr MW et al (1995) The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol 128(6):1243–1253 Schaffler A, Buchler C (2007) Concise review: adipose tissue-derived stromal cells–basic and clinical implications for novel cell-based therapies. Stem Cell 25(4):818–827. doi:10.1634/stemcells.2006-0589 Fukiage K, Aoyama T, Shibata KR et al (2008) Expression of vascular cell adhesion molecule-1 indicates the differentiation potential of human bone marrow stromal cells. Biochem Biophys Res Comm 365(3):406–412. doi:10.1016/j.bbrc.2007.10.149 Gronthos S, Zannettino AC, Hay SJ et al (2003) Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 116(Pt 9):1827–1835 Fujita R, Tamai K, Aikawa E et al (2015) Endogenous mesenchymal stromal cells in bone marrow are required to preserve muscle function in mdx mice. Stem Cell 33(3):962–975. doi:10.1002/stem.1900 Ren G, Zhao X, Zhang L et al (2010) Inflammatory Cytokine-Induced Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 in Mesenchymal Stem Cells Are Critical for Immunosuppression. J Immunol 184(5):2321–2328. doi:10.4049/jimmunol.0902023 Castro-Manrreza ME, Montesinos JJ (2015) Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res 2015:394917. doi:10.1155/2015/394917 Shih IM (1999) The role of CD146 (Mel-CAM) in biology and pathology. J Pathol 189(1):4–11. doi:10.1002/(SICI)1096-9896(199909)189:1<4:AID-PATH332>3.0.CO;2-P Martin-Rendon E, Sweeney D, Lu F et al (2008) 5-Azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies. Vox Sang 95(2):137–148. doi:10.1111/j.1423-0410.2008.01076.x Rider DA, Dombrowski C, Sawyer AA et al (2008) Autocrine fibroblast growth factor 2 increases the multipotentiality of human adipose-derived mesenchymal stem cells. Stem Cells 26(6):1598–1608. doi:10.1634/stemcells.2007-0480 Maleki M, Ghanbarvand F, Reza Behvarz M et al (2014) Comparison of mesenchymal stem cell markers in multiple human adult stem cells. Int J Stem Cell 7(2):118–126. doi:10.15283/ijsc.2014.7.2.118 Espagnolle N, Guilloton F, Deschaseaux F et al (2014) CD146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment. J Cell Mol Med 18(1):104–114. doi:10.1111/jcmm.12168 Crisan M, Yap S, Casteilla L et al (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3(3):301–313. doi:10.1016/j.stem.2008.07.003 Sacchetti B, Funari A, Michienzi S et al (2007) Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131(2):324–336. doi:10.1016/j.cell.2007.08.025 Blocki A, Wang Y, Koch M et al (2013) Not all MSCs can act as pericytes: functional in vitro assays to distinguish pericytes from other mesenchymal stem cells in angiogenesis. Stem Cells Dev 22(17):2347–2355. doi:10.1089/scd.2012.0415 Caplan AI (2008) All MSCs are pericytes? Cell Stem Cell 3(3):229–230. doi:10.1016/j.stem.2008.08.008 Baksh D, Yao R, Tuan RS (2007) Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 25(6):1384–1392. doi:10.1634/stemcells.2006-0709 Russell KC, Phinney DG, Lacey MR et al (2010) In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cell 28(4):788–798. doi:10.1002/stem.312 Sorrentino A, Ferracin M, Castelli G et al (2008) Isolation and characterization of CD146 + multipotent mesenchymal stromal cells. Exp Hematol 36(8):1035–1046. doi:10.1016/j.exphem.2008.03.004 Corselli M, Chin CJ, Parekh C et al (2013) Perivascular support of human hematopoietic stem/progenitor cells. Blood 121(15):2891–2901. doi:10.1182/blood-2012-08-451864 Park TS, Gavina M, Chen CW et al (2011) Placental perivascular cells for human muscle regeneration. Stem Cell Dev 20(3):451–463. doi:10.1089/scd.2010.0354 Chen CW, Okada M, Proto JD et al (2013) Human pericytes for ischemic heart repair. Stem Cell 31(2):305–316. doi:10.1002/stem.1285 Houlihan DD, Mabuchi Y, Morikawa S et al (2012) Isolation of mouse mesenchymal stem cells on the basis of expression of Sca-1 and PDGFR-α. Nat Protoc 7(12):2103–2111. doi:10.1038/nprot.2012.125 Hoffman AM, Paxson JA, Mazan MR et al (2011) Lung-derived mesenchymal stromal cell post-transplantation survival, persistence, paracrine expression, and repair of elastase-injured lung. Stem Cell Dev 20(10):1779–1792. doi:10.1089/scd.2011.0105 Jiang MH, Li G, Liu J et al (2015) Nestin(+) kidney resident mesenchymal stem cells for the treatment of acute kidney ischemia injury. Biomaterials 50:56–66. doi:10.1016/j.biomaterials.2015.01.029 Morikawa S, Mabuchi Y, Kubota Y et al (2009) Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med 206(11):2483–2496. doi:10.1084/jem.20091046 Pinho S, Lacombe J, Hanoun M et al (2013) PDGFRalpha and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. J Exp Med 210(7):1351–1367. doi:10.1084/jem.20122252 Fathke C, Wilson L, Hutter J et al (2004) Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. Stem Cell 22(5):812–822. doi:10.1634/stemcells.22-5-812 Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276–1312. doi:10.1101/gad.1653708 Hellstrom M, Kalen M, Lindahl P et al (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126(14):3047–3055 Ball SG, Shuttleworth CA, Kielty CM (2007) Platelet-derived growth factor receptor-alpha is a key determinant of smooth muscle alpha-actin filaments in bone marrow-derived mesenchymal stem cells. Int J Biochem Cell Biol 39(2):379–391. doi:10.1016/j.biocel.2006.09.005 Ball SG, Shuttleworth A, Kielty CM (2012) Inhibition of platelet-derived growth factor receptor signaling regulates Oct4 and Nanog expression, cell shape, and mesenchymal stem cell potency. Stem Cell 30(3):548–560. doi:10.1002/stem.1015 Rajkumar VS, Shiwen X, Bostrom M et al (2006) Platelet-Derived Growth Factor-β Receptor Activation Is Essential for Fibroblast and Pericyte Recruitment during Cutaneous Wound Healing. Am J Pathol 169(6):2254–2265. doi:10.2353/ajpath.2006.060196 Tokunaga A, Oya T, Ishii Y et al (2008) PDGF receptor beta is a potent regulator of mesenchymal stromal cell function. J Bone Miner Res Off J Am Soc Bone Miner Res 23(9):1519–1528. doi:10.1359/jbmr.080409 Tigges U, Komatsu M, Stallcup WB (2013) Adventitial pericyte progenitor/mesenchymal stem cells participate in the restenotic response to arterial injury. J Vasc Res 50(2):134–144. doi:10.1159/000345524000345524 Ball SG, Worthington JJ, Canfield AE et al (2014) Mesenchymal stromal cells: inhibiting PDGF receptors or depleting fibronectin induces mesodermal progenitors with endothelial potential. Stem Cell 32(3):694–705. doi:10.1002/stem.1538 Lendahl U, Zimmerman LB, McKay RD (1990) CNS stem cells express a new class of intermediate filament protein. Cell 60(4):585–595 Mendez-Ferrer S, Michurina TV, Ferraro F et al (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466(7308):829–834. doi:10.1038/nature09262 Isern J, Martin-Antonio B, Ghazanfari R et al (2013) Self-renewing human bone marrow mesenspheres promote hematopoietic stem cell expansion. Cell Report 3(5):1714–1724. doi:10.1016/j.celrep.2013.03.041 Wan M, Li C, Zhen G et al (2012) Injury-activated transforming growth factor beta controls mobilization of mesenchymal stem cells for tissue remodeling. Stem Cells 30(11):2498–2511. doi:10.1002/stem.1208 Zhen G, Wen C, Jia X et al (2013) Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med 19(6):704–712. doi:10.1038/nm.3143 Follenzi A, Raut S, Merlin S et al (2012) Role of bone marrow transplantation for correcting hemophilia A in mice. Blood 119(23):5532–5542. doi:10.1182/blood-2011-07-367680 Ip JE, Wu Y, Huang J et al (2007) Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell 18(8):2873–2882. doi:10.1091/mbc.E07-02-0166 Shi M, Li J, Liao L et al (2007) Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematol-Hematol J 92(7):897–904. doi:10.3324/haematol.10669 Potapova IA, Brink PR, Cohen IS et al (2008) Culturing of human mesenchymal stem cells as three-dimensional aggregates induces functional expression of CXCR4 that regulates adhesion to endothelial cells. J Biol Chem 283(19):13100–13107. doi:10.1074/jbc.M800184200 Liu H, Liu S, Li Y et al (2012) The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One 7(4):e34608. doi:10.1371/journal.pone.0034608 Cheng Z, Ou L, Zhou X et al (2008) Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther J Am Soc Gene Ther 16(3):571–579. doi:10.1038/sj.mt.6300374 Wang Z, Wang Y, Wang Z et al (2015) Engineered mesenchymal stem cells with enhanced tropism and paracrine secretion of cytokines and growth factors to treat traumatic brain injury. Stem Cell 33(2):456–467. doi:10.1002/stem.1878 Yu Q, Liu L, Lin J et al (2015) SDF-1alpha/CXCR4 Axis Mediates The Migration of Mesenchymal Stem Cells to The Hypoxic-Ischemic Brain Lesion in A Rat Model. Cell J 16(4):440–447 Du Z, Wei C, Yan J et al (2013) Mesenchymal stem cells overexpressing C-X-C chemokine receptor type 4 improve early liver regeneration of small-for-size liver grafts. Liver Transpl Off Publ Am Assoc Study Liver Dis Int Liver Transpl Soc 19(2):215–225. doi:10.1002/lt.23577 Gang EJ, Bosnakovski D, Figueiredo CA et al (2007) SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 109(4):1743–1751. doi:10.1182/blood-2005-11-010504 Hamamoto H, Gorman JH 3rd, Ryan LP et al (2009) Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage. Annals Thorac Surg 87(3):794–801. doi:10.1016/j.athoracsur.2008.11.057 Ortiz LA, Dutreil M, Fattman C et al (2007) Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 104(26):11002–11007. doi:10.1073/pnas.0704421104 Herrera MB, Bussolati B, Bruno S et al (2007) Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 72(4):430–441. doi:10.1038/sj.ki.5002334 Lee RH, Seo MJ, Pulin AA et al (2009) The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 113(4):816–826. doi:10.1182/blood-2007-12-128702 Zhou BO, Yue R, Murphy MM et al (2014) Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 15(2):154–168. doi:10.1016/j.stem.2014.06.008